GSN and Sepsis: The route of exogenous gelsolin administration has been reported to determine the therapeutic efficiency of pGSN, since CLP-induced sepsis in rats was inhibited by subcutaneous and intravenous, but not intraperitoneal injection of plasma gelsolin, which strongly indicates the necessity of systemic action of pGSN, in order to improve the clinical outcomes of septic subjects [14].